Skip to main content
XLO
NASDAQ Life Sciences

Xilio Q3 10-Q: $122.2M Cash to Q1 2028, But Operating Loss Widens to $11.7M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.97
Mkt Cap
$59.221M
52W Low
$6.465
52W High
$11.9
52W Position info
39% above low
Off High info
25% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

XLO sits 39% above its 52-week low of $6.465.

Summary

Xilio's Q3 10-Q shows a $5.9 million net loss that was helped by a $4.8 million non-cash warrant gain while the operating loss widened to $11.7 million; $122.2 million of cash funds operations into Q1 2028, and 3.4 million Series C warrants expire December 2, 2026 with a strike reset if the stock stays below $10.50.


Key Events · Earnings and Guidance · XLO

  • Q3 Net Loss Flattered by Warrant Gain

    Net loss was $5.9 million versus $16.3 million a year earlier, but the improvement came largely from a $4.8 million non-cash gain on warrant remeasurement; the operating loss widened to $11.7 million from $1.9 million.

  • Cash of $122.2M Funds Operations Into Q1 2028

    Cash and cash equivalents fell to $122.2 million from $137.5 million at December 31, 2025, with runway guided into the first quarter of 2028.

  • Series C Warrant Reset Looms December 2

    3,443,388 Series C warrants at a $10.50 strike expire December 2, 2026; if the closing price is below the strike on December 2, the exercise price resets to the December 1 close and expiry extends to December 31. A full cash exercise would raise up to $36.2 million.

  • New Chief Medical Officer Hired

    Yariv Houvras signed an employment agreement dated August 13, 2026 as Chief Medical Officer: $525,000 base salary, 40% target bonus, a 105,000-share option and a $75,000 sign-on bonus.


Analysis · XLO · Life Sciences

The $5.9 million headline net loss is flattered by a $4.8 million non-cash gain on warrant remeasurement; the actual operating loss widened to $11.7 million from $1.9 million a year earlier as R&D rose to $14.8 million. Cash of $122.2 million funds operations into the first quarter of 2028, which removes near-term financing pressure, but the runway assumes no further draws. The real overhang is the 3,443,388 Series C warrants: they expire December 2, 2026, and if the stock is still below the $10.50 strike on December 1 the exercise price resets to that closing price and the expiry extends to December 31 — a full cash exercise would bring in up to $36.2 million, but a reset would reprice that capital raise downward. Also disclosed: a new Chief Medical Officer agreement (Yariv Houvras, $525,000 base, 105,000-share option) and an increase in the 2022 Inducement Plan reserve to 623,555 shares.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XLO was trading at $8.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.2M. The 52-week trading range was $6.47 to $11.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XLO - Latest Insights

XLO
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.17
Real-time Price: $8.97 info
Change: -$0.200 (-2%) info
Market Cap: $59.221M info
XLO
Aug 12, 2026, 7:40 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $8.97 info
Change: -$0.230 (-2%) info
Market Cap: $59.221M info
XLO
Aug 12, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $8.97 info
Change: -$0.230 (-2%) info
Market Cap: $59.221M info
XLO
Aug 12, 2026, 7:34 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $8.97 info
Change: -$0.230 (-2%) info
Market Cap: $59.221M info
XLO
Jun 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.31
Real-time Price: $8.97 info
Change: +$0.660 (+8%) info
Market Cap: $59.221M info